The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1281
March 10, 2008
View Complete Issue         Table of Contents 2019 
Nebivolol (Bystolic) for Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nebivolol (Bystolic) for Hypertension
March 10, 2008 (Issue: 1281)
Nebivolol (Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart failure.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nebivolol (Bystolic) for Hypertension
Article code: 1281a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.